ArticleMedicine2026
Integrated analysis of the circRNA-miRNA-mRNA regulatory network underlying the therapeutic effects of Jinkui Shenqi Wan, a traditional Chinese medicine formula, in diabetic kidney disease: A network pharmacology and bioinformatics study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Jinkui Shenqi Wan (JKSQW) is a classical traditional Chinese medicine (TCM) formula used for diabetic kidney disease (DKD), but its molecular mechanisms remain incompletely defined. While non-coding RNAs (ncRNAs) are increasingly recognized as key regulators in DKD, their role in the therapeutic action of JKSQW has not been systematically explored. Accordingly, we aimed to elucidate the potential mechanisms of JKSQW in DKD by integrating a circRNA-miRNA-mRNA regulatory network into a network pharmacology framework. Bioactive constituents and putative targets of JKSQW were retrieved from TCMSP and STITCH and mapped to UniProt. DKD-related differentially expressed mRNAs (DEmRNAs) were obtained from GEO (GSE1009; GPL16791) and analyzed using DESeq2 (Benjamini-Hochberg adjusted P < .05; |log2FC| > 2). circRNA-miRNA interactions were predicted using miRcode and cross-checked with starBase when available; miRNA-mRNA interactions were integrated from miRDB, miRTarBase, and TargetScan, retaining pairs supported by ≥ 2 resources or validated entries. Overlapping drug-disease targets underwent STRING-based protein-protein interaction (PPI) analysis, GO/KEGG enrichment with clusterProfiler, and molecular docking (AutoDock Vina). Docked complexes were visualized in PyMOL and annotated with PLIP. Fifty constituents mapped to 218 targets; 543 DEmRNAs were identified in DKD, with 20 overlapping genes considered potential therapeutic targets. PPI analysis highlighted hubs HTR2A, EGFR, TOP2A, CDK1, and MYC. Integration of ncRNA predictions yielded a circRNA-miRNA-mRNA network comprising 50 circRNAs, 32 miRNAs, and 20 mRNAs, revealing axes such as circ_0000962-miR‑15a‑5p-CDK1. Enrichment implicated p53 and AGE-RAGE signaling in apoptosis, fibrosis, and oxidative stress. Docking showed stigmasterol exhibited favorable affinities with HTR2A (-8.3 kcal/mol), EGFR (-7.6), TOP2A (-7.8), and CDK1 (-8.7). JKSQW may exert multi-component, multi-target protection against DKD by engaging ncRNA-mediated regulation and protein hubs within p53 and AGE-RAGE pathways. These findings provide a modern pharmacological rationale for this TCM formula and a transferable framework for ceRNA-integrated network analyses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.